阿霞制药公司(Amphastar Pharmaceuticals,股票代码:AMPH)11月7日早盘大跌10.22%,引发市场广泛关注。公司近期披露的2024财年第三季度财报显示,营收及利润均未达分析师预期,或是引发投资者担忧的主因。
根据财报数据,阿霞公司第三季度调整后每股收益为0.96美元,低于分析师平均预期的0.99美元。营收同比增长5.9%至1.91亿美元,但也未达预期的1.95亿美元。第三季度净收入为4,043万美元。
过去三个月内,分析师对阿霞公司未来盈利预期有所下调,平均预期下降约2.8%。不过,分析师目前仍给予该股"买入"的评级,并预计公司长期业绩有望好转。阿霞制药今年迄今股价累计下跌16.6%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.